Advanced search for publications
Enter your keywords
Disease-modifying therapies for Alzheimer’s disease
A new generation of disease-modifying therapies (DMTs) for Alzheimer’s disease are in development and the potentially eligible population for these agents is very large. The aim of this evaluation report is to briefly discuss the effectiveness and safety of lecanemab and donanemab and attempt to estimate their potential impact on patients and services in the […]
Teriparatide for treatment of osteoporosis in men aged over 50 years
The aim of this evaluation report is to review the evidence for the efficacy, safety, and tolerability of teriparatide for use in male patients for osteoporosis treatment.
Insulin aspart Sanofi (Trurapi): Biosimilar Insulin Aspart
Overview Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing. Insulin aspart Sanofi (Trurapi®▼) is the first biosimilar of insulin aspart (NovoRapid®). It is licensed for the treatment of diabetes […]
Omalizumab and dupilumab for chronic rhinosinusitis with nasal polyps
Overview Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing. Omalizumab and dupilumab are indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic […]
Solriamfetol for obstructive sleep apnoea
Solriamfetol is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). This publication reviews its efficacy and safety, and the limitations of the evidence. Solriamfetol is also licensed […]
Solriamfetol for narcolepsy
Solriamfetol is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy with or without cataplexy. This publication reviews its efficacy and safety, and the limitations of the evidence. Solriamfetol is also licensed to improve wakefulness and reduce EDS in adults with obstructive sleep apnoea (see separate RDTC evaluation).
Doxylamine and pyridoxine (Xonvea) for the treatment of nausea and vomiting of pregnancy
Xonvea® is the only drug specifically licensed in the UK for the treatment of nausea and vomiting in pregnancy. It is intended for use in women with symptoms of nausea and vomiting in pregnancy that do not respond to conservative management.
ActiPatch for the management of localised musculoskeletal pain
ActiPatch® (BioElectronics) is a wearable pulsed shortwave therapy device for the management of localised musculoskeletal pain (sometimes referred to as pulsed electromagnetic field therapy – PEMF). The device is placed directly over the source of pain and held in place with wraps, adhesives, bandages or clothing, and can be used for up to 24 hours […]
Naloxone nasal spray for opioid overdose
Naloxone 1.8 mg nasal spray (Nyxoid®, Mundipharma) is a single dose solution licensed in adults and adolescents aged 14 years and over. It is indicated for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both nonmedical and healthcare settings.